BPC-157 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Once daily subcutaneous injection is the cadence for musculoskeletal applications, while gut applications use 500 mcg orally twice daily. Injection is placed within 1 to 2 cm of the injury site when anatomy allows: BPC-157 enters systemic circulation rapidly, but local injection puts a higher concentration at the target before dilution. For injuries that are hard to reach, such as spine or deep hip, abdominal subcutaneous injection is the practical alternative. Oral dosing works because BPC-157 is uniquely stable in gastric acid, surviving over 24 hours, which makes direct contact with intestinal tissue effective for gut indications. At 10 mg/mL a full dose falls between 2.5 and 7.5 units, so an insulin syringe marked to 30 units reads these small volumes more accurately than a full 100 unit barrel.

Results Timeline

Sequence described in the research record. Individual response varies.

• Week 1: restored local blood flow is often the first reported change, described as the injured area warming up.
• Weeks 1 to 2: reduced pain and swelling in most reports.
• Weeks 4 to 8: full therapeutic effect for acute musculoskeletal injury.
• Weeks 8 to 12: chronic conditions and tendinopathy generally need the longer block to reach the same point.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 250 mcg = 2.5 units, 500 mcg = 5 units, 750 mcg = 7.5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12+ months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid repeated freezing and thawing.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Label each vial with the reconstitution date and the 10 mg/mL concentration; a 1.0 mL fill is a small working volume, so draw carefully and keep the stopper clean between doses.

Supplies Needed

Planning is based on a 4 to 8 week course at 500 mcg per day subcutaneously near the injury site, which works out to 3.5 mg per week.

Peptide Vials (BPC-157, 10 mg vial):

• Four weeks totals 14 mg, about 2 vials, and eight weeks totals 28 mg, about 3 vials; a 12 week course at 500 mcg daily and an 8 week course at 750 mcg daily each total 42 mg, about 5 vials.

Insulin Syringes (U-100):

• Per week (daily SC): 7 syringes (U-100, 30 unit markings preferred at this concentration).
• Four weeks: 28 syringes. Eight weeks: 56. Twelve weeks: 84.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site.
• Eight weeks of daily injections: 112 swabs, so two 100 count boxes. Twelve weeks: 168 swabs.

Important Notes

Practical considerations for consistency and safety.

• Inject within 1 to 2 cm of the injury site when anatomically possible, since local concentration drives the strongest effect. Abdominal subcutaneous injection is the fallback for injuries that are hard to reach.
• Defined courses, not indefinite use: 4 to 8 weeks for acute injury and 8 to 12 weeks for chronic conditions. No tolerance develops, but most protocols are self limiting.
• Oral is the route of choice for gut applications, because BPC-157 survives gastric acid for over 24 hours and direct contact with intestinal tissue is the mechanism for gut healing. Subcutaneous is preferred for musculoskeletal targets.
• Contraindications and cautions: active cancer, because BPC-157 promotes angiogenesis and cell migration and the 2025 narrative review by Katzman flags theoretical pathologic angiogenesis as a concern for cancer history or proliferative conditions; pregnancy or breastfeeding, given insufficient safety data; and caution within 2 weeks of surgery, since excessive angiogenesis may complicate wound closure timing.
• Stacking partners: TB-500 in the Wolverine Stack, where BPC-157 restores the vascular foundation and TB-500 handles cell migration and structural remodeling; GHK-Cu starting at week 3 or later for collagen quality during remodeling rather than initial repair; and KPV at 200 to 500 mcg subcutaneously daily when chronic inflammation is actively blocking repair.
• Regulatory Note: FDA moved BPC-157 to Category 2 in 2023, meaning it cannot be legally compounded. WADA prohibits it under class S0, with no TUE available and 4 year sanctions, so athletes subject to testing should avoid it entirely. DoD bans it as a supplement ingredient for military personnel. Pentadeca Arginate (PDA) is the arginate salt form that emerged after the ruling: the peptide sequence is identical, patent data shows about 1,000 times better gastric stability than the acetate form at pH 3.0, the claim of 90% oral bioavailability has no supporting study, no peer reviewed PDA specific research exists, and PDA sits in a regulatory gray area rather than legal clarity.

How This Works

BPC-157 addresses two bottlenecks that stall repair. The first is blood flow restoration: it activates the VEGFR2, Akt, and eNOS signaling cascade and upregulates VEGF, driving endothelial sprout formation and capillary network restoration in ischemic tissue, which is why many reports describe injured areas warming up within the first week. The second is inflammation modulation without suppression: it reduces TNF alpha, IL-1 beta, and IL-6 while leaving the rebuilding signal intact, normalizes the vagal inflammatory reflex, and reduces mast cell degranulation. That mechanism is fundamentally different from NSAIDs and steroids, which block inflammation but also impair collagen quality by suppressing the same signals that drive repair. For gut applications, BPC-157 signals epithelial cells to close gaps in the intestinal barrier through ZO-1 and occludin tight junction upregulation, sealing a leaky barrier at the protein level. For connective tissue, it mobilizes fibroblasts, upregulates Type I and Type III collagen, improves tensile strength, and reduces adhesion formation, producing functional tissue with organized fibers rather than disorganized scar. The peptide is uniquely stable in gastric acid, surviving over 24 hours, which is why oral dosing works for gastrointestinal indications where direct mucosal contact is the goal.

Benefits & Side Effects

Observations from the published record.

• Gut healing: restoration of tight junction integrity through ZO-1 and occludin, reduced mucosal inflammation, and preclinical efficacy in IBD and colitis models with restored barrier function and high remission rates.
• Tendon and ligament repair: accelerated healing in transected Achilles models, improved tensile strength within 2 weeks against 4 to 6 weeks for controls, and reduced fibrosis and scar tissue formation. Muscle repair shows enhanced regeneration in laceration models and preserved muscle function after tendon trauma.
• Neuroprotection: peripheral nerve protection from ischemic and chemical injury, with axonal sprouting that supports sensation recovery and pain reduction. Post surgical recovery shows angiogenesis driven faster tissue repair in preclinical models, while controlled human data are still emerging.
• Emerging human data: an interstitial cystitis pilot (2024, n=12) reported 10 of 12 complete resolution; an IV safety study (2025, n=2) found no adverse effects on cardiac, hepatic, renal, or glucose biomarkers; and a knee pain retrospective (2021, n=17) reported 91.6% with significant improvement.
• Evidence quality: the 2025 systematic review by Ghanem in HSS J screened 544 articles and included 36, of which 35 were preclinical and 1 clinical, concluding that high quality clinical evidence remains limited and recommending caution. The 2025 narrative review by Katzman flags theoretical pathologic angiogenesis for cancer history or proliferative conditions.
• Side effects: mild injection site irritation, reported rarely, and mild GI upset with oral dosing in sensitive individuals. Published reports show no immunosuppression, no hormonal disruption, and no metabolic side effects at therapeutic doses, though no multi year human data exists.

Lifestyle Factors

Complementary strategies for best outcomes.

• Load management: BPC-157 accelerates repair that is already underway and does not replace appropriate rest or rehab progressions. Pairing it with rehab or physical therapy matters for musculoskeletal work, since load progressions determine what gets built.
• Protein at 1.6 to 2.2 g per kg of body weight supports the substrate side of collagen synthesis.
• Vitamin C, zinc, and copper are cofactors for collagen cross linking, and deficiencies blunt repair quality.
• Sleep of 7 to 9 hours plus minimal NSAID use during the course: most tissue repair signaling runs during sleep, and NSAIDs suppress the same inflammatory signals that drive repair.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Sikiric P et al. BPC-157: comprehensive review of regenerative properties and clinical applications (Curr Pharm Des, 2020).
2. Sikiric P et al. Brain gut axis and BPC 157: theoretical and practical implications (Curr Neuropharmacol, 2019).
3. Chang CH et al. BPC 157 enhances growth hormone receptor expression in tendon fibroblasts (Molecules, 2018).
4. Ghanem S et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: systematic review (HSS J, 2025).
5. Katzman BM et al. Regeneration or Risk? Narrative Review of BPC-157 (Curr Rev Musculoskelet Med, 2025).
6. Krivic A et al. BPC 157 prevents muscle weakness following tendon trauma (J Appl Physiol, 2014).